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Autosomal dominant hypocalcemia type 1 (ADH1) is caused by germline gain-of-function muta-
tions of the calcium-sensing receptor (CaSR) and may lead to symptomatic hypocalcemia, inap-
propriately lowserumPTHconcentrationsandhypercalciuria.NegativeallostericCaSRmodulators,
known as calcilytics, have been shown to normalize the gain-of-function associated with ADH-
causing CaSR mutations in vitro and represent a potential targeted therapy for ADH1. However,
the effectiveness of calcilytic drugs for the treatment ofADH1-associated hypocalcemia remains to
be established. We have investigated NPS 2143, a calcilytic compound, for the treatment of ADH1
by in vitro and in vivo studies involving a mouse model, known as Nuf, which harbors a gain-of-
function CaSR mutation, Leu723Gln. Wild-type (Leu723) and Nuf mutant (Gln723) CaSRs were
expressed in HEK293 cells, and the effect of NPS 2143 on their intracellular calcium responses was
determinedby flowcytometry.NPS2143wasalsoadministeredas a single ipbolus towild-typeand
Nufmice and plasma concentrations of calcium and PTH, and urinary calcium excretionmeasured.
In vitro administration of NPS 2143 decreased the intracellular calcium responses of HEK293 cells
expressing the mutant Gln723 CaSR in a dose-dependent manner, thereby rectifying the gain-of-
function associated with the Nuf mouse CaSR mutation. Intraperitoneal injection of NPS 2143 in
Nufmice led to significant increases in plasma calcium and PTH without elevating urinary calcium
excretion. These studiesof amousemodelwithanactivatingCaSRmutationdemonstrateNPS2143
to normalize the gain-of-function causing ADH1 and improve the hypocalcemia associated with
this disorder. (Endocrinology 156: 3114–3121, 2015)
Autosomal dominant hypocalcemia type 1 (ADH1)and ADH2 (Online Mendelian Inheritance in Man
[OMIM] numbers 601198 and 615361) are caused by
germline gain-of-function mutations of the calcium-sens-
ing receptor (CaSR) and G protein subunit -11 (1–4),
respectively, which play a pivotal role in the parathyroid
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and renal regulation of extracellular calcium (Ca2o) con-
centrations. Gain-of-function CaSR mutations have been
demonstrated to induce biased signaling responses that
involve the preferential activationof phospholipaseC-me-
diated intracellular calcium (Ca2i) mobilizations (Figure
1) (5), which lead to decreased PTH secretion and in-
creased urinary calcium excretion (2, 4, 6). ADH1-asso-
ciated mutations may also enhance CaSR biosynthesis by
stabilizing newly formedCaSRs in an active conformation
that protects against proteasomal degradation (7, 8).
Approximately 50% of patients with ADH1 develop
hypocalcemic symptoms such as paraesthesia, carpo-
pedal spasms, and seizures (1, 3, 9–12). Although ADH1
is associatedwith increased circulating phosphate concen-
trations and inappropriately low or normal PTH concen-
trations, this is considered to represent a distinct disease
entity from hypoparathyroidism, because affected indi-
viduals generally have PTH concentrations that are de-
tectable and may either be below or within the reference
range (1, 9, 10), and also a relative hypercalciuria that is
characterized by urinary calcium to creatinine ratios that
are within or above the reference range (1, 9). Ectopic
calcification of the kidneys and basal ganglia is a common
featureofADH1andaffectsmore than35%ofpatients (1,
10, 12). PatientswithCaSRmutations that lead to a severe
gain-of-function may also develop a Bartter-like syn-
drome characterized by hypokalemic alkalosis, renal salt
wasting, andhyperreninemic hyperaldosteronism (11, 13,
14). Active vitamin D metabolites, combined with ade-
quate dietary calcium intake and/or use of calcium sup-
plements, are currently the mainstay of treatment for
symptomatic ADH1 patients. However, their use predis-
poses affected individuals to the development of marked
hypercalciuria, nephrocalcinosis, nephrolithiasis, and re-
nal impairment (1, 9).
Compounds that selectively bind to the CaSR and al-
losterically inhibit the function of this G protein-coupled
receptor represent a potential targeted therapy for ADH
(15–18). Indeed, these negative allosteric CaSR modula-
tors, which are known as calcilytics, have been demon-
strated, in vitro, to improve the gain-of-function associ-
ated with ADH-causing CaSR mutations (19–22). The
mechanismof actionof calcilytic drugs involves binding to
plasma membrane CaSRs and diminishing receptor sig-
naling responses in the presence of orthosteric agonist
(20). Moreover, prolonged exposure of cells expressing
gain-of-function mutant CaSRs to calcilytic drugs may
facilitate internalization of these allosteric modulators,
which then bind and destabilize the conformation of nas-
cent CaSRs, thus leading to enhanced proteasomal deg-
radation of mutant receptors (Figure 1) (7, 8). However,
some gain-of-functionmutations locatedwithin the CaSR
transmembrane domain (TMD), which is predicted to be
the binding site for allosteric CaSR modulators (23, 24),
have been shown to impair the effectiveness of calcilytic
drugs (Supplemental Figure 1) (19–22, 25). Moreover, it
is unclear whether calcilytic drugs may improve the hy-
pocalcemia of ADH1 while minimizing the risk of hyper-
calciuric renal disease. We have assessed the effectiveness
of a phenylalkylamine calcilytic compound, known as
NPS 2143, for the treatment of ADH1 using a mouse
model, known as Nuf, which harbors a germline
nonconstitutively activating mutation, Leu723Gln, lo-
cated within the second intracellular loop of the CaSR
TMD (Supplemental Figure 1) (26). Nuf mice were orig-
inally identified for having opaque flecks in the nucleus of
the lens and have an ADH phenotype characterized by
hypocalcemia, hyperphosphatemia, inappropriately re-
duced plasma PTH concentrations, and ectopic calcifica-
tion (26).Before embarkingonan invivoassessmentof the
efficacy of the calcilytic NPS 2143 in rectifying the Nuf
mouse hypocalcemia, we used first an in vitro functional
assay to determine whether NPS 2143 may normalize the
gain-of-function associated with theNuf Leu723Gln mu-
tation, because some TMD-located ADH-associated
CaSRmutations have been reported to be unresponsive or
partially responsive to calcilytic drugs (19–22, 25).
Figure 1. Schematic representation of the mechanism of action of
NPS 2143. NPS 2143 binds to the TMD of plasma membrane-
expressed CaSRs and decreases Ca2o-mediated signaling responses
such as Ca2i mobilization. Prolonged exposure of CaSR-expressing
cells to NPS 2143 may lead to the internalization of this calcilytic
compound, which is considered to bind to newly formed CaSRs within
the endoplasmic reticulum (ER), and destabilize their active
conformation, thus leading to protein misfolding and proteasomal
degradation (8), which would in turn diminish the pool of receptors
available for trafficking to the plasma membrane. EC, extracellular.
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Materials and Methods
In vitro assessment of NPS 2143 on the functional
responses of the Leu723Gln mutant CaSR
Wild-typeandmutantCaSR-pEGFP-N1constructsweregen-
erated as described previously (26) and transiently transfected
into HEK293 cells using Lipofectamine Plus (Invitrogen), as de-
scribed (2, 26). The wild-type andmutant CaSRs were function-
ally assessed bymeasuring alterations inCa2i concentrations in
response to changes in Ca2o concentrations, as described pre-
viously (2, 26). Forty-eight hours after transfection, the cells
were harvested, washed in calcium- andmagnesium-freeHanks’
balanced salt solution (Invitrogen), and loaded with 1-g/mL
indo-1-acetoxymethylester (Molecular Probes) for 1 hour at
37°C. After removal of free dye, the cells were resuspended in 1
mL of calcium- and magnesium-free Hanks’ balanced salt solu-
tion and maintained at 37°C. Transfected HEK293 cells were
incubatedwith either a 15%aqueous solution of 2-hydroxypro-
pyl--cyclodextrin (Sigma) (vehicle) orNPS2143 for onehour at
the following concentrations: 0nM, 20nM, 40nM, and 80nM.
Flow-assisted cell sortingwasperformedwithaCytomationMo-
Flo flow cytometer (Dako-Cytomation) equipped with an argon
laser (Coherent Radiation), as described (26). Baseline fluores-
cence ratiowasmeasured for 2minutes, the fluorescence ratio vs
timewas recorded, and data were collected for 2minutes at each
Ca2o concentration. Cytomation summit software was used to
determine the peak mean fluorescence ratio of the transient re-
sponse after each individual stimulus expressed as a normalized
response, as previously reported (26, 27). The EC50 (ie, Ca
2
o
concentration required for 50% of the maximal response) for
each normalized concentration-response curve was determined.
In vivo administration of NPS 2143 to Nuf mice
Nufmice were maintained on the inbred 102/H background,
which is a substrain bred at the Mary Lyon Centre. Mice were
kept in accordance with United Kingdom Home Office welfare
guidance and project license restrictions. Mice were fed ad libi-
tumon a commercial diet (which contained 1.2%calcium, 0.8%
phosphate, and 3000-IU/kg vitamin D; Rat andMouse Diet No.
3; Special Diet Services). A single bolus of NPS 2143 or vehicle
(15% aqueous solution of 2-hydroxypropyl--cyclodextrin)
was administered by ip injection to wild-type,Nuf/, andNuf/
Nuf mice aged between 16 and 20 weeks (n  8–14 for all
groups). An aqueous solution of 2-hydroxypropyl--cyclodex-
trin was used as the drug vehicle for NPS 2143, because this has
previously been demonstrated to be effective at dissolving this
calcilytic compound and to be safe and well tolerated in rodent
studies (15, 16, 28). Based on the findings of previous rodent
studies involving NPS 2143 (16, 28), a dose of 30 mg/kg was
administered to wild-type and Nuf mice. Plasma samples were
obtained at either 0, 1, 4, or 24 hours by tail vein or terminal
bleed. Urine samples were obtained from untreatedmice ormice
that had been bled at 1 hour after administration ofNPS 2143 or
drug vehicle alone and then immediately housed in metabolic
cages (Tecniplast) for a 24-hour period and fed ad libitum on
water andpowdered chow (29).Urine sampleswere analyzed for
calcium and creatinine and plasma samples analyzed for total
calcium, albumin, sodium, potassium, phosphate, urea, creati-
nine, and alkaline phosphatase activities using a Beckman
Coulter AU680 analyzer, as previously described (29). Plasma
calciumwas adjusted for albumin using the formula: ((albumin-
mean albumin)0.02) calcium, as reported (29). The calcium
to creatinine clearance ratio (CCCR) was calculated using the
formula UCa/PCa  PCr/UCr, where UCa is the urinary concen-
tration of calcium in mmol/L, PCa is the plasma concentration
of adjusted calcium in mmol/L, UCr is the urinary concentration
of creatinine in mmol/L, and PCr is the plasma concentration of
creatinine in mmol/L (29). Plasma PTH concentrations were de-
termined using an ELISA formouse intact PTH (Immutopics), as
described (30).
Statistical analyses
For the in vitro functional expression studies, the mean EC50
from 4 separate transfection experiments was used for statistical
comparison by using the Mann-Whitney U test. For the in vivo
studies, the data from male and female mice were pooled for
analysis, because no statistically significant differences were ob-
served between these groups. A Mann-Whitney U test was used
to compare biochemical and metabolic variables between wild-
type and affected Nuf mice, in which the Bonferroni correction
for multiple testing was applied. P .05 was considered signif-
icant for all analyses.
Results
Effect of the calcilytic NPS 2143 on the function of
the mutant Leu723Gln CaSR
The responses of wild-type and mutant CaSRs to alter-
ations in Ca2o concentrations were assessed, after tran-
sient transfection of HEK293 cells, by measurements of
Ca2i concentrations (Figure 2). In agreement with pre-
vious findings (26), the mutant Gln723 CaSR showed a
significant leftward shift in its concentration-response
curve when compared with the wild-type Leu723 CaSR,
thereby demonstrating that the mutant CaSR is activated
by a lower [Ca2]o than the wild type, consistent with this
leading to a gain of CaSR function. Indeed, the mutant
Gln723 CaSR had a significantly (P .01) reduced EC50
(1.94  0.07mM) when compared with the EC50 of the
wild type (2.53 0.14mM) (Figure 2 andTable 1). A dose
titration of the calcilytic agent, NPS 2143, in HEK293
cells expressing the mutant Gln723 CaSR revealed that
NPS 2143 at a concentration of 20nM led to a rightward
shift of the mutant receptor concentration-response curve
(EC50 of 2.79  0.19, P  .33 compared with wild type)
(Table 1), so that this was indistinguishable to that of the
wild-type Leu723 CaSR (Figure 2), and thus the function
of the mutant receptor was normalized. The addition of
higher doses of NPS 2143 (40nM and 80nM) led to a
marked rightward shift of the concentration-response
curve, so that the mutant Gln723 CaSR displayed a loss-
of-function with significantly raised EC50 values of more
than or equal to 4.0mM (P .01) (Figure 2 and Table 1).
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Effect of the calcilytic NPS 2143 on the
hypocalcemia of Nuf mice
The in vitro studies revealed that NPS 2143 was effec-
tive in rectifying the gain-of-function of the mutant
Gln723 CaSR, and we therefore pursued studies to deter-
mine whether ip injection of the calcilytic compound
NPS 2143 could improve the hypocalcemia associated
with Nuf mice. Untreated Nuf/ and Nuf/Nuf mice
were significantly hypocalcemic and hyperphosphatemic
(P  .001), and had significantly reduced plasma PTH
concentrations when compared with age-matched wild-
typemice (Figure 3).No significant alterationswere noted
in plasma concentrations of sodium, potassium, creati-
nine, and alkaline phosphatase activity between wild-type
and affectedNufmice (Table 2 and Supplemental Tables 1
and 2). Intraperitoneal bolus administration of NPS 2143
resulted in a significant (P .001) rise in plasma calcium
concentrations at 1 hour after injection in wild-type,
Nuf/, andNuf/Nufmice (Table 2, Supplemental Tables
1 and 2, and Figure 3, A–C). Thus, NPS 2143 successfully
improved the hypocalcemia associated with Nuf/ and
Nuf/Nufmice compared with mice given the drug vehicle
alone or untreated mice. At 4 hours after NPS 2143 ad-
ministration, plasma calcium values remained signifi-
cantly elevated inwild-type and affectedNuf/mice com-
pared with respective untreated mice (Figure 3, A and B),
and at 24 hours, plasma calciumconcentrations decreased
to levels that were not significantly different from mice
given the drug vehicle alone or untreated mice (Figure 3,
A–C). Furthermore, NPS 2143 treatment resulted in a
marked rise in plasma PTH concentrations in wild-type
and affected Nuf mice at 1 hour (Figure 3, D–F). PTH
concentrations decreased to baseline values at 24 hours
afterNPS2143administration (Figure3,D–F).Treatment
with NPS 2143 did not significantly alter plasma phos-
phate concentrations in wild-type or affected Nuf mice
comparedwith control groupmice (Table2, Supplemental
Tables 1 and 2, and Figure 3, G–I). Indeed, administration
ofNPS 2143 or the drug vehicle alonewas associatedwith
significant increases in plasma phosphate inwild-type and
affectedNufmice at 1 and 4 hours compared with respec-
tive untreated mice (Figure 3, G–I), and these increases in
plasma phosphate were accompanied by elevations in
plasma urea and creatinine concentrations (Table 2 and
Figure 3, J–L), whichmay indicate dehydration leading to
renal impairment. NPS 2143 administration was other-
wisewell tolerated andnot associatedwith adverse effects.
A single ip dose of NPS 2143 had no significant effect on
urinary calcium parameters such as 24-hour urinary cal-
cium excretion, calcium to creatinine ratio, or CCCR (Ta-
ble 3 and Supplemental Tables 3 and 4).
Discussion
The calcilytic compound, NPS 2143, was assessed as a
potential targeted therapy for ADH1 by studies involving
Nuf mice, which harbor a gain-of-function Leu723Gln
CaSR mutation (26). NPS 2143 was used as it induces
more prolonged elevations in circulating PTH concentra-
tions than other calcilytic drugs (17, 31) and has been
shown to be safe and well tolerated in rodent studies (15).
Table 1. EC50 Values for Wild-Type Leu723 and
Mutant Gln723 CaSRs in the Presence of Different
NPS 2143 Concentrations
CaSR Construct
EC50 (mM)
Mean
Value SEM n
P Value
(vs WT)
Leu723 (WT)  vehicle 2.53 0.14 4 —
Gln723 (m)  vehicle 1.94 0.07 4 .01
Gln723 (m)  20nM
NPS 2143
2.79 0.19 4 .33
Gln723 (m)  40nM
NPS 2143
3.97 0.10 4 .01
Gln723 (m)  80nM
NPS 2143
4.56 0.09 4 .01
The number (n) of separate transfection experiments is indicated. WT,
wild type; m, mutant.
Figure 2. Effect of NPS 2143 on the concentration-response curve of
the mutant Gln723 CaSR in transfected HEK293 cells. HEK293 cells
were transiently transfected with wild-type or the mutant CaSR-EGFP
construct. Single, live cells were loaded with indo-1-
acetoxymethylester, which emits fluorescence at 525 nm. NPS 2143
was added at 0nM, 20nM, 40nM, and 80nM concentrations to
HEK293 cells transfected with the mutant Gln723 CaSR-EGFP. Cells
transfected with the CaSR were selected by fluorescence-activated cell
sorting, and the Ca2o-evoked increases in Ca
2
i concentrations were
measured. The concentration-response curves of the untreated
(dashed line) and NPS 2143-treated (dotted lines) mutant Gln723
receptor were compared with the untreated wild-type (WT) Leu723
CaSR-EGFP (solid line). The increments in Ca2o concentrations from
0mM to 10mM are shown on the x-axis, and the Ca2i response,
which was measured as a percentage of the maximum normalized
response, is shown on the y axis (mean  SEM of 4 estimations).
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Figure 3. Plasma adjusted calcium, PTH, phosphate, and creatinine concentrations after ip injection of either NPS 2143 or drug vehicle. Plasma concentrations
of (A–C) adjusted calcium, (D–F) PTH, (G–I) phosphate, and (J–L) creatinine were measured in untreated (U) mice, or 1, 4, or 24 hours after mice were given an ip
bolus injection of control (C) or drug (D) solutions (n 4–14 for all groups). $, P .001 for a comparison between untreated (U)Nuf/ orNuf/Nufmice and
respective untreated wild-type mice. **, P .01 and ***, P .001 for a comparison between respective wild-type,Nuf/, orNuf/Nufmice given control (C) or
drug (D) solutions. †, P .05 and ‡, P .01 for a comparison between wild-type,Nuf/, orNuf/Nufmice given control (C) or drug (D) solutions and respective
untreated (U) mice.
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However, previous in vitro studies have indicated that
NPS 2143 may not be a suitable therapy for all gain-of-
function CaSR mutations (19–22, 25). Indeed, ADH-as-
sociated CaSR mutations, such as Ala835Asp and
Ala843Glu, which are located close to the Glu837 TMD
residue that is critical for NPS 2143 binding (Supplemen-
tal Figure 1) (19, 21, 32), have been demonstrated to com-
pletely abrogate the action of NPS 2143, whereas ADH-
associated TMD CaSR mutations located away from
known NPS 2143 binding residues, such as Glu767Gln,
Leu773Arg and Asn802Ile, may partially diminish the ef-
ficacy of this calcilytic compound (Supplemental Figure 1)
(20, 22, 25). We therefore evaluated the effects of NPS
2143, in vitro, on theNuf Leu723Gln mutation, which is
also located in the TMD (Supplemental Figure 1), before
assessing its efficacy in vivo. Our use of a cell-based assay
that functionally expressed the Leu723Gln CaSRmutant,
revealed the gain-of-function associated with the
Leu723Gln mutation to be wholly responsive to NPS
2143. This calcilytic acted in a dose-dependent manner
and restored the Leu723Gln mutant EC50 to a value that
was indistinguishable to the wild-type receptor, thereby
normalizing the sensitivity of the CaSR to Ca2o. Indeed,
the Nuf Leu723Gln mutation responded to nanomolar
concentrations of NPS 2143, whereas previous in vitro
studies of CaSR mutations leading to ADH, indicate that
Table 2. Effect of NPS 2143 Treatment on Plasma Biochemical Parameters
Parameters
Genotypes
Wild Type Nuf/ Nuf/Nuf
Untreated Vehicle Only Drug Untreated Vehicle Only Drug Untreated Vehicle Only Drug
Sodium (mmol/L) 146  0.7 147  0.7 146  0.6 145  0.6 146  0.7 148  0.6 146  0.7 146  0.8 146  0.7
(n  12) (n  7) (n  8) (n  12) (n  8) (n  7) (n  11) (n  8) (n  8)
Potassium (mmol/L) 4.9  0.1 4.8  0.2 4.9  0.1 4.7  0.2 4.8  0.1 4.7  0.2 4.5  0.2 4.9  0.1 4.8  0.2
(n  10) (n  8) (n  8) (n  12) (n  7) (n  7) (n  11) (n  7) (n  8)
Urea (mmol/L) 11.3  0.7 12.4  0.6e 12.9  0.6e 11.6  0.6 13.7  0.6e 13.5  0.5e 11.9  0.6 14.3  0.7e 14.3  0.7e
(n  10) (n  10) (n  12) (n  11) (n  9) (n  12) (n  12) (n  8) (n  10)
Creatinine (mol/L) 14.6  0.9 17.4  0.7c 17.3  1.0 13.6  0.7 19.2  1.2d 18.3  1.0c 13.9  0.5 18.8  1.2c 18.3  1.0c
(n  10) (n  10) (n  12) (n  10) (n  10) (n  12) (n  10) (n  8) (n  10)
Albumin (g/L) 31.1  0.5 29.7  0.5 29.7  0.4 29.8  0.7 28.9  0.5 28.3  0.5 29.8  0.4 28.4  0.6 28.5  0.5
(n  13) (n  10) (n  13) (n  14) (n  14) (n  14) (n  13) (n  12) (n  11)
Calcium (mmol/L) 2.50  0.06 2.58  0.06 2.83  0.06b 1.87  0.04a 1.88  0.04 2.21  0.06b 1.62  0.05a 1.64  0.05 1.93  0.04b
(n  13) (n  10) (n  13) (n  14) (n  14) (n  13) (n  12) (n  12) (n  11)
Phosphate (mmol/L) 2.21  0.13 2.66  0.07c 2.64  0.13 3.22  0.11a 4.03  0.15d 3.50  0.2 4.03  0.12a 4.63  0.22 4.55  0.2
(n  10) (n  10) (n  12) (n  11) (n  10) (n  12) (n  11) (n  8) (n  10)
ALP (U/L) 131  7.1 128  7.4 128  8.3 121  7.3 122  8.1 142  8.8 123  7.2 118  5.0 147  15
(n  10) (n  10) (n  12) (n  11) (n  11) (n  12) (n  10) (n  10) (n  12)
PTH (pmol/L) 9.4  2.8 9.9  2.8 37.4  7.1b 4.3  1.8a 6.3  1.8 25.3  5.0b 2.6  0.8a 3.4  1.2 18.4  4.2b
(n  14) (n  6) (n  12) (n  14) (n  6) (n  12) (n  13) (n  6) (n  10)
Plasma biochemical values were measured in untreated mice and at 1 hour after administration of NPS 2143 or drug vehicle only. All values are
expressed as mean  SEM. Plasma calcium concentrations were normalized to the mean plasma albumin concentration. ALP, alkaline phosphatase
activity.
a P  .001 for a comparison between untreated Nuf/ or Nuf/Nuf mice and respective untreated wild-type mice.
b P  .001 for a comparison of mice given NPS 2143 vs respective mice given drug vehicle only.
c P  .05 for a comparison between wild-type, Nuf/, or Nuf/Nuf mice given vehicle only or NPS 2143 and respective untreated mice.
d P  .01 for a comparison between wild-type, Nuf/, or Nuf/Nuf mice given vehicle only or NPS 2143 and respective untreated mice.
e P  .05 before Bonferroni correction for a comparison between wild-type, Nuf/, or Nuf/Nuf mice given vehicle only or NPS 2143 and respective
untreated mice.
Table 3. Effect of NPS 2143 Treatment on Urinary Calcium Parameters
Parameters
Genotypes
Wild Type Nuf/ Nuf/Nuf
Untreated Vehicle Only Drug Untreated Vehicle Only Drug Untreated Vehicle Only Drug
24-h Ca 3.4  0.8 3.6  1.0 3.8  0.9 2.6  0.3 2.0  0.2 2.7  0.6 2.4  0.5 2.4  0.2 1.9  0.4
(n  8) (n  7) (n  7) (n  7) (n  6) (n  7) (n  7) (n  6) (n  6)
Ca/Cr 0.31  0.05 0.28  0.04 0.23  0.02 0.29  0.05 0.24  0.05 0.20  0.02 0.24  0.03 0.18  0.02 0.15  0.03
(n  8) (n  7) (n  7) (n  7) (n  6) (n  7) (n  7) (n  6) (n  6)
CCCR 0.0017  0.0002 0.0019  0.0002 0.0014  0.0002 0.0019  0.0005 0.0024  0.0005 0.0018  0.0002 0.0020  0.0002 0.0022  0.0004 0.0013  0.0002
(n  8) (n  7) (n  7) (n  7) (n  6) (n  7) (n  7) (n  6) (n  6)
Urinary calcium excretion (24-h Ca) and urinary calcium to creatinine ratio (Ca/Cr) were measured using urine samples obtained over a 24-hour
period from untreated mice or from mice administered NPS 2143 or drug vehicle alone. The CCCR was measured using plasma samples obtained
at 1 hour, and urine samples were obtained over a 24-hour period from untreated mice or from mice administered NPS 2143 or drug vehicle
alone. Urinary calcium excretion values are shown as mol/24 hours. No significant differences in urinary calcium parameters were observed
between untreated mice and mice given the drug vehicle or between NPS 2143-treated mice and mice given the drug vehicle alone. All values are
expressed as mean  SEM.
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micromolar concentrations of this calcilytic drug may be
required to rectify associated signal transduction abnor-
malities (19, 20, 22). The responsiveness of the
Leu723Gln mutation to low doses of NPS 2143 may be
explained by the finding that this mutation is not consti-
tutively activating and induced less than 25%reduction in
the EC50 value compared with the wild-type CaSR,
whereas CaSR mutations leading to ADH1 generally
cause amore than 30%reduction in the EC50 value (1, 19,
21, 22, 25). Thus, such in vitro assays that characterize the
function of mutant CaSRs may provide a personalized
medicine approach to the selectionof appropriate targeted
therapies for specific ADH1-causing CaSR mutations.
Such targeted therapiesmay include phenylalkylamines or
the quinazolinone class of calcilytic compounds that have
also recently been shown to normalize the gain-of-func-
tion associatedwithNPS2143-resistantADH1mutations
in vitro (21) and have potential for the management of
patients harboring such mutations.
In support of these findings demonstrating the in vitro
efficacy of NPS 2143 for the Nuf mouse Leu723Gln CaSR
mutation, in vivo administration of this calcilytic led to 4- to
5-fold increases in plasma PTHconcentrations in bothwild-
type and affected Nuf mice, which is in keeping with a re-
ported study involving wild-type rats (16). These elevations
in plasma PTH were accompanied by a 0.25–0.30 mmol/L
increase in plasma calcium values in wild-type,Nuf/, and
Nuf/Nufmice and indicate that gene dosage did not impact
on drug efficacy. Moreover, the amelioration of hypocalce-
mia in Nuf mice was not associated with any increase in
urinary calcium excretion, which typically occurs when
ADH1patients are treatedwithactivevitaminDmetabolites
(1, 9). Indeed, NPS 2143 may be expected to lower urinary
calcium excretion, which has been reported in wild-type rat
studies (28). The Nuf mice urine biochemical parameters
were assessed using 24-hour urine samples, and any reduc-
tion in urinary calcium excretion may not have been appar-
ent if the renal effects of a single dose ofNPS2143 lasted less
than 24 hours. A longer-term study that involves repetitive
dosing and a period of acclimatization to themetabolic cage
environment may be required to more accurately determine
the effects of NPS 2143 on urinary calcium excretion (29).
The duration of action of ip injected NPS 2143 on plasma
calcium and PTH concentrations was short-lived compared
withoraladministrationof thisdrug. Indeed,deliveryofNPS
2143 to wild-type rats by oral gavage has been previously
shown to result in prolonged elevations of circulating PTH
concentrations that lasted more than 4 hours (15, 28),
whereas plasma PTH had decreased by 4 hours after ip in-
jection in the present study. Of note, NPS 2143 administra-
tion did not lead to a lowering of plasma phosphate concen-
trations, despite inducing a marked rise in plasma PTH.
Althoughanobserved lackof a phosphate-lowering effect of
NPS 2143 may be consequence of the blood sampling time
points, plasma phosphate concentrations were actually
shown to increase after administration of NPS 2143 or the
drug vehicle alone. The most likely cause of the hyperphos-
phatemia was a decrease in renal function that occurred in
mice receiving the drug or control solutions. Although ip
injection represents awidely usedmethodof drugdelivery in
rodents, this drug administration route may be associated
with increased physiological stress (33), thereby leading to
reducedfluid intakeanddehydration. Inkeepingwithstudies
involving wild-type rats (28), NPS 2143 had a selective ac-
tion on plasma calciumand PTHbut did not influence other
biochemical parameters such as plasma sodium, potassium
or creatinine. However, the present study involved single
doseadministrationofNPS2143,andrepetitivedosingstud-
ies are required to confirm the efficacy of calcilytic com-
pounds in inducing sustained increases incirculatingcalcium
and PTH concentrations in the setting of ADH1 and to de-
termine whether these CaSR-targeted drugs may also ame-
liorate the hyperphosphatemia and hypercalciuria associ-
ated with this disorder.
In summary, these studies involving Nuf mice with an
activating CaSR mutation demonstrate that NPS 2143-me-
diated allosteric inhibition of the CaSR is able to rectify the
molecular defect underlying ADH1 and also improve the
reduced plasma calcium and PTH levels that are associated
with this disorder. These findings indicate that the calcilytic
NPS 2143, or related compounds, have potential as targeted
therapies for the hypocalcemia associated with ADH1.
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